Imagine a parasite from pork that travels to the brain and causes seizures. This project is testing a better combination of medicines and a blood test to find the disease faster. It's like upgrading a broken GPS system to help doctors get patients to the right treatment more efficiently.
WHO guidelines for neurocysticercosis are ignored in national policies, leaving millions of patients without optimal treatment. This leads to high rates of preventable epilepsy and death in endemic regions.
A validated combined antiparasitic treatment regimen and a serological testing implementation strategy. It also includes training materials for healthcare workers.
If you are a drug manufacturer dealing with low adoption of existing treatments — this project developed a combined treatment regimen that improves quality of life. This provides a validated clinical pathway for expanding market reach in Tanzania and Zambia.
If you are a diagnostics company dealing with imprecise screening for zoonotic diseases — this project evaluated the impact of serological testing on patient outcomes. This data helps in positioning blood tests as a cost-effective alternative to expensive imaging.
If you are a consultancy dealing with the gap between WHO guidelines and national policy — this project developed an implementation strategy to remove barriers to uptake. This can be used as a blueprint for deploying other health technologies in endemic regions.
The project specifically includes a work package to demonstrate the cost-effectiveness and cost-benefit of the proposed health technologies. Based on available project data, the exact monetary savings are not yet listed.
The project is currently being validated in Tanzania and Zambia. It aims to provide a blueprint for implementation research that can be applied to other healthcare systems.
Based on available project data, there is no mention of specific patents or licensing terms; the focus is on evaluating the impact of existing serological testing.
The project engages policy and decision-makers to ensure research results are integrated into national and international guidelines.
The project period runs from 2023-05-01 to 2027-04-30, suggesting results will be finalized by April 2027.
The consortium is heavily academic, consisting of 4 universities and 1 other entity across 4 countries (BE, IT, TZ, ZM). With 0% industry participation, the project is currently driven by research and clinical validation rather than commercial development, though it is coordinated by an Italian SME-type social enterprise.
Contact R-EVOLUTION WORLDWIDE SRL for details on the implementation strategy.
Contact us to identify potential diagnostic partners for the serological test validation.
